Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PS-341 (Velcade) in Advanced NSCLC
NCT00200382Phase 2
Key facts
- Status
- Terminated
- Start
- May 2004
- Primary completion
- May 2007
- Countries
- 1
- Sponsor
- Rasim Gucalp
- Modality
- Small Molecules, Modified Peptides
- Drugs
- bortezomib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by Rasim Gucalp. Primary endpoint: Objective Response Rate. Started May 2004; status: terminated.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Chemotherapy-naïve patients with Stage IIIB or IV NSCLC, ECOG 0-2, and adequate organ function.
04
Endpoints
Primary
Objective Response Rate
Secondary
Time to Progression
Overall Survival
Safety and Toxicity
Beyond the preview
Go deeper on NCT00200382.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00200382.